GGHC
RLAY icon

Gilder Gagnon Howe & Co’s Relay Therapeutics RLAY Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-68,606
Closed -$755K – 276
2023
Q4 		$755K Sell
68,606
-63,604
-48% -$537K 0.01% 215
2023
Q3 		$1.11M Sell
132,210
-53,892
-29% -$580K 0.02% 206
2023
Q2 		$2.34M Buy
186,102
+83,502
+81% +$1.04M 0.03% 194
2023
Q1 		$1.69M Sell
102,600
-5,358
-5% -$96.1K 0.03% 181
2022
Q4 		$1.61M Sell
107,958
-35,562
-25% -$681K 0.03% 181
2022
Q3 		$3.21M Buy
143,520
+8,637
+6% +$190K 0.06% 155
2022
Q2 		$2.26M Sell
134,883
-139,400
-51% -$2.99M 0.04% 166
2022
Q1 		$8.21M Sell
274,283
-522,464
-66% -$12.7M 0.08% 151
2021
Q4 		$24.5M Buy
796,747
+35,004
+5% +$1.11M 0.14% 129
2021
Q3 		$24M Sell
761,743
-73,795
-9% -$2.48M 0.12% 145
2021
Q2 		$30.6M Sell
835,538
-1,184,923
-59% -$39M 0.15% 137
2021
Q1 		$69.8M Sell
2,020,461
-46,470
-2% -$2.02M 0.38% 76
2020
Q4 		$85.9M Buy
2,066,931
+41,430
+2% +$1.87M 0.43% 74
2020
Q3 		$86.3M Buy
+2,025,501
New +$77.2M 0.53% 63

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Gilder Gagnon Howe & Co's RLAY Position: Q1 2024 in Review

Gilder Gagnon Howe & Co sold out of Relay Therapeutics (RLAY) in Q1 2024, closing a stake of 68,606 shares — an estimated $755K sold.

Gilder Gagnon Howe & Co first reported a position in RLAY in Q3 2020 and held it in 14 quarters. The position peaked at $86.3M in Q3 2020. 189 funds tracked by Wall St. Rank hold RLAY as of Q1 2024.

  • Gilder Gagnon Howe & Co reported no remaining Relay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 68,606 Relay Therapeutics shares in Q1 2024, an estimated $755K.
  • Gilder Gagnon Howe & Co first reported a position in Relay Therapeutics in Q3 2020 and held it in 14 quarters.
  • Gilder Gagnon Howe & Co's Relay Therapeutics position peaked at $86.3M in Q3 2020.
  • 189 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2024.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2024, filed 15 May 2024.